1 / 1

AsPC-1

( X 10 4 ). ( X 10 4 ). 2.0. 2.0. 1.5. 1.5. 1.0. 1.0. 0.5. 0.5. 0. 0. Control + DMSO. Control + DMSO. DN-Nrf2 + DMSO. DN-Nrf2 + DMSO. Control + 100 m M Cisplatin. Control + 100 m M Cisplatin. DN-Nrf2 + 100 m M Cisplatin. DN-Nrf2 + 100 m M Cisplatin. Supplementary 2. A.

keaira
Download Presentation

AsPC-1

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. (X 104) (X 104) 2.0 2.0 1.5 1.5 1.0 1.0 0.5 0.5 0 0 Control + DMSO Control + DMSO DN-Nrf2 + DMSO DN-Nrf2 + DMSO Control + 100 mM Cisplatin Control + 100 mM Cisplatin DN-Nrf2 + 100 mM Cisplatin DN-Nrf2 + 100 mM Cisplatin Supplementary 2 A AsPC-1 cell number ** ** ** 0 24 48 72 (hr) B Colo-357 cell number * ** ** 0 24 48 72 (hr) Supplementary 2.Inhibition of Nrf2 activity with dominant negative Nrf2 (DN-Nrf2) reduced cell numbers in AsPC-1 (A) and Colo-357 (B). AsPC-1 and Colo-357 cells (1 x 104) were transfected with control or DN-Nrf2 vector for 24 hr. Then, the transfected cells were incubated with DMSO or 100 μM Cisplatin. Alive cells were counted under a light-microscope at indicated times. *, p < 0.05; **, p < 0.01.

More Related